Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals reported a significant decline in profitability for Q1 2026, with net income falling by 74.7% to $6.42 million and diluted EPS decreasing to $0.14. This occurred despite a slight increase in net revenues to $171.17 million. The company experienced a substantial rise in cost of revenues and research and development expenses, impacting gross profit and operating income. However, net cash provided by operating activities increased by 36.4% year-over-year.

Amphastar Pharmaceuticals reported Q1 2026 financial results with net revenues of $171.2 million, largely flat year-over-year. GAAP net income significantly decreased to $6.4 million ($0.14 per diluted share) from $25.3 million in Q1 2025. Adjusted non-GAAP net income also fell to $19.5 million ($0.42 per diluted share). The company highlighted the launch of Ipratropium Bromide HFA and a new licensing agreement for a synthetic corticotropin compound, alongside pipeline advancements.